Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report
| Autor: | Eduardo Guerrero-Hurtado, Eva Romá-Sánchez, M Rosa Gómez-Portero, Mireya Fernández-Sánchez, José Luis Poveda-Andrés, Hugo Ribes-Artero, Javier García-Pellicer |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Embryology
Pregnancy Fetus medicine.medical_specialty Tofacitinib business.industry Obstetrics Health Toxicology and Mutagenesis Context (language use) Toxicology medicine.disease Fetal exposure Clinical trial First trimester Psoriatic arthritis embryonic structures Pediatrics Perinatology and Child Health Medicine business Developmental Biology |
| Zdroj: | Birth Defects Research. 113:1275-1279 |
| ISSN: | 2472-1727 |
| Popis: | Introduction Preclinical studies with tofacitinib demonstrated teratogenic effects. Data about effects on human fetuses are limited and current recommendations are to immediately discontinue the treatment. Our purpose is to report a case of exposure to tofacitinib during the first trimester of pregnancy. Case summary A 40-year-old woman with psoriatic arthritis became pregnant during the first month of treatment with tofacitinib. Tofacitinib was interrupted immediately, and parents were informed about the possible risks of teratogenicity. At the end of pregnancy, our patient gave birth to a healthy newborn. Conclusion All the available evidence of tofacitinib exposure during pregnancy in humans belongs to outcomes of unexpected pregnancies in the context of clinical trials and post-marketing cases. This case may contribute to enriching available data about teratogenic risks of tofacitinib exposure during pregnancy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text